Cal Biotech said it will buy out its R&D; partnership.
- Share via
The Mountain View, Calif., biotechnology company said it will offer $2.5 million in cash, 2.5 million common shares and 1.2 million common stock warrants for the 2,492 outstanding units of Biotechnology Research Partners. Additionally, it will forgive some partner indebtedness. The partnership’s projects include cardiovascular, growth and animal vaccine products.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
